{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:05Z","timestamp":1790240585984,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The health care use (HCU) burden of transplant-associated thrombotic microangiopathy (TA-TMA) and its treatments are unknown. The objective of this study was to investigate inpatient costs associated with meeting criteria for TA-TMA in the first year after hematopoietic cell transplant (HCT). This institutional review board\u2013approved retrospective multicenter study included serial children who underwent HCT from 1 January 2015 to 1 July 2019. A standardized unit cost (adjusted for geographic location, differences in cost of living, and inflation) for inpatient hospitalization was extracted from the Pediatric Health Information System data and linked to clinical data. Both total cost and cost per day from 15\u00a0days before stem cell infusion to 1-year after HCT were calculated. Among allogeneic (allo) transplant recipients, after adjusting for severe grade 3\/4 acute graft-versus-host disease (GVHD), infections, and HLA mismatch, costs were not different in TA-TMA (n\u00a0= 137) vs no TA-TMA (n\u00a0= 238). Severe GVHD was significantly associated with increased costs. Among allo high-risk (HR) TMA-TMA, unadjusted costs were significantly higher in the eculizumab-treated cohort (n\u00a0= 19) than in the supportive care group (n\u00a0= 36). However, after adjusting for gastrointestinal bleeding that occurred disproportionately in the eculizumab (n\u00a0= 6) vs supportive care (n\u00a0= 0) cohort, eculizumab treatment was not associated with increased total costs. More studies are needed to determine the etiology of increased HCU costs in those with HR-TA-TMA and predict those more likely to benefit from eculizumab, reducing HCU and improving outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011078","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T15:17:40Z","timestamp":1703776660000},"page":"1220-1233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Pediatric transplant\u2013associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle L.","family":"Schoettler","sequence":"first","affiliation":[{"name":"1Division Blood and Marrow Transplantation, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lehmann","sequence":"additional","affiliation":[{"name":"2Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Kao","sequence":"additional","affiliation":[{"name":"2Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"2Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[{"name":"3Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-0800","authenticated-orcid":false,"given":"Satheesh","family":"Chonat","sequence":"additional","affiliation":[{"name":"1Division Blood and Marrow Transplantation, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Williams","sequence":"additional","affiliation":[{"name":"1Division Blood and Marrow Transplantation, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B.","family":"London","sequence":"additional","affiliation":[{"name":"2Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Duncan","sequence":"additional","affiliation":[{"name":"2Dana Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher","family":"Dandoy","sequence":"additional","affiliation":[{"name":"3Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"1","key":"2024031114152013200_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A\u00a0pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024031114152013200_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2024031114152013200_bib3","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024031114152013200_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose carboplatin\/etoposide\/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2024031114152013200_bib5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2024031114152013200_bib6","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin Transplant"},{"issue":"2","key":"2024031114152013200_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024031114152013200_bib8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation\u2013associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024031114152013200_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","article-title":"Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study","volume":"58","author":"Svec","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2024031114152013200_bib10","first-page":"22","article-title":"The most expensive drug in the world: to continue or discontinue, that is the question","volume":"33","author":"Khedraki","year":"2016","journal-title":"Fed Pract"},{"issue":"6","key":"2024031114152013200_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41409-018-0390-3","article-title":"Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?","volume":"54","author":"Vaughn","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2024031114152013200_bib12","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2024031114152013200_bib13","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024031114152013200_bib14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2024031114152013200_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archpediatrics.2012.1266","article-title":"Prioritization of comparative effectiveness research topics in hospital pediatrics","volume":"166","author":"Keren","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"2024031114152013200_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024031114152013200_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41409-023-01910-y","article-title":"Total and out-of-pocket expenditures for patients undergoing hematopoietic cell transplantation","volume":"58","author":"Patnaik","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024031114152013200_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41409-019-0688-9","article-title":"Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation","volume":"55","author":"Ricci","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024031114152013200_bib19","first-page":"384","article-title":"Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation","volume":"55","author":"Bourgeois","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024031114152013200_bib20","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1007\/s00520-020-05382-4","article-title":"Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation","volume":"28","author":"Yu","year":"2020","journal-title":"Support Care Cancer"},{"issue":"12","key":"2024031114152013200_bib21","first-page":"1503","article-title":"A\u00a0US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"2024031114152013200_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hon.2310","article-title":"Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study","volume":"35","author":"Ye","year":"2017","journal-title":"Hematol Oncol"},{"key":"2024031114152013200_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-6367(23)00089-1","article-title":"Prospective study of allogeneic pediatric transplant associated thrombotic microangiopathy- novel prognostic markers, biologic interaction and poor response to eculizumab no title","author":"Schoettler","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2024031114152013200_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1220\/2217644\/blooda_adv-2023-011078-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1220\/2217644\/blooda_adv-2023-011078-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T10:15:48Z","timestamp":1710152148000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1220\/506892\/Pediatric-transplant-associated-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011078","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}